

## betamethasone dipropionate 0.05% SPRAY (SERNIVO)

### Diagnoses Considered for Coverage:

- Psoriasis
- Inflammatory skin conditions (dermatoses)
- Atopic dermatitis

### Coverage Criteria:

#### 1. For diagnoses listed above:

- Dose does not exceed FDA label maximum, **and**
- Inadequate response or intolerable side effect with generically available topical betamethasone AND one other preferred topical steroid in the high to very high potency class.

Preferred High Potency Steroids	<ul style="list-style-type: none"> <li>• augmented betamethasone dipropionate 0.05% cream (Diprolene AF)</li> <li>• betamethasone dipropionate 0.05% cream, ointment (Maxivate, Diprosone)</li> <li>• betamethasone valerate 0.1% ointment (Betatrex, Valisone)</li> <li>• fluocinonide 0.05% cream (Lidex E)</li> <li>• fluocinonide 0.05% cream, gel, ointment, solution (Lidex)</li> <li>• mometasone 0.1% ointment (Elocon)</li> <li>• triamcinolone acetonide 0.5% cream (Kenalog)</li> <li>• triamcinolone acetonide 0.5% ointment (Aristocort HP)</li> </ul>
Preferred Very High Potency Steroids	<ul style="list-style-type: none"> <li>• augmented betamethasone dipropionate 0.05% gel, ointment, lotion (Diprolene)</li> <li>• clobetasol 0.05% cream, ointment, solution, gel, cream emollient (Temovate)</li> <li>• halobetasol 0.05% cream, ointment (Ultravate)</li> </ul>

### Coverage Duration:

#### References:

1. Sernivo. Prescribing Information. DPT Laboratories, Ltd., San Antonio, TX. 3/2020

Effective Date: 11/30/2022